Pharmacotherapy of Prostate Cancer
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 15 November 2025 | Viewed by 42
Special Issue Editor
Interests: prostate cancer; androgen receptor; castration resistance; small peptide drug; metabolomics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Prostate cancer has always represented a major challenge worldwide, with key issues including resistance to androgen receptor pathway inhibitors (ARPIs), neuroendocrine progression, and limited durable responses to immunotherapy. This Special Issue will highlight novel therapeutic strategies reshaping this field, with a focus on the following topics:
- Next-Generation AR-Targeting Agents: Oral PROTACs, AR degraders, and selective AR-V7 inhibitors in overcoming resistance.
- DNA Damage Repair (DDR) Therapeutics: PARP inhibitor combinations, ATR/ATM kinase inhibitors, and biomarkers for homologous recombination deficiency.
- Radiopharmaceuticals: PSMA-targeted alpha/beta-emitters (e.g., 225Ac-PSMA-617) and their integration into immunotherapy.
- Neuroendocrine Differentiation: DLL3-targeted therapies and epigenetic modulators (EZH2/BET inhibitors).
- Immunotherapy Advances: Bispecific T-cell engagers, CAR-T cell engineering, and approaches to reversing "cold" tumor microenvironments.
We invite you to share your latest research results in this field, including, but not limited to, the following areas:
- Original research on preclinical/clinical drug development;
- Phase I-III trial results;
- Reviews on emerging targets (e.g., ferroptosis inducers, antibody–drug conjugates);
- Prostate cancer biomarkers.
We hope that this Special Issue will improve our understanding of this malignant disease and encourage discussion among frontline physicians, to improve treatment outcomes for prostate cancer patients.
Dr. Benyi Li
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- clinical
- treatment
- prostate cancer imaging
- targeted therapy
- immunotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
